Inhibitory effect of verbascoside on xanthine oxidase activity.
In this study, we analyzed the inhibitory effect of verbascoside against xanthine oxidase (XOD) in vitro by using animal model and in vivo by direct inhibition assay. Results showed that verbascoside could reduce uric acid in rat serum and inhibit XOD activity in rat liver. The IC50value of restraining XOD activity was 81.11mgmL-1. Fluorescence chromatographic analysis and circular dichroism spectroscopy indicated that the secondary structures of XOD were changed after incubation with verbascoside. The docking simulation showed that verbascoside could enter into the active site of XOD and form hydrogen bonding with amino acid residues (such as Lys-1045, Arg-880, Arg-912, Glu-1261 and Gln-1194). The results suggested that verbascoside, which is a naturally occurring water-soluble antioxidant, could be a potential low-toxicity XOD inhibitor for hyperuricemia treatment.
State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China; School of Food Science and Technology, Nanchang University, Nanchang 330047, China.
Yin
Y
Wan
State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China.
Bin
B
Zou
State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China.
Hailong
H
Zeng
Institute for Food and Drug Control, Pingxiang 337055, China.
Lunning
L
Zhang
The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Ming
M
Chen
State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China; School of Food Science and Technology, Nanchang University, Nanchang 330047, China. Electronic address: fuguiming@ncu.edu.cn.
Guiming
G
Fu
D000818:Animals; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D005960:Glucosides / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D033461:Hyperuricemia / Q000188:drug therapy / Q000201:enzymology; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D062105:Molecular Docking Simulation; D010636:Phenols / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D017433:Protein Structure, Secondary; D051381:Rats; D017207:Rats, Sprague-Dawley; D014527:Uric Acid / Q000097:blood; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D059808:Polyphenols
D004791:Enzyme Inhibitors; D005960:Glucosides; D010636:Phenols; D014527:Uric Acid; D014969:Xanthine Oxidase; C058956:acteoside; D059808:Polyphenols
Circular dichroism spectra; Fluorescence chromatographic; Inhibitory activity; Molecular simulation; Verbascoside; Xanthine oxidase